Lutropin Alfa

Lutropin alfa (Luveris) was a real, FDA-approved recombinant LH for a narrow population of women with profound LH deficiency — approved on an accelerated pathway in 2004, pulled from the US market in 2012 for commercial reasons, and formally stripped of its FDA approval in 2016 after the company couldn't complete the confirmatory trial it had agreed to.

A narrow population, by design

Lutropin alfa is recombinant human luteinizing hormone (LH), added to FSH therapy specifically for women with profound hypogonadotropic hypogonadism (WHO Group I anovulation) — patients whose bodies lack enough endogenous LH to support the estrogen production that FSH-driven follicle growth depends on. Most IVF and ovulation-induction patients have adequate endogenous LH already, which is why this drug only ever addressed a narrow slice of the fertility-treatment population.

Approved, then formally withdrawn

The FDA approved lutropin alfa (as Luveris) on 8 October 2004 under accelerated-approval regulations, based on a dose-finding trial (European Recombinant Human LH Study Group, J Clin Endocrinol Metab 1998, PMID 9589647) — which meant EMD Serono committed to completing a confirmatory postmarketing study on time-to-pregnancy. The company discontinued US marketing in 2012, and in April of that same year requested withdrawal of the approval, stating it wasn't feasible to complete the required trial. The FDA published the formal withdrawal in the Federal Register on 12 April 2016 (81 FR 21558) — a real, if slow-moving, example of the accelerated-approval accountability mechanism actually being enforced when a company can't deliver the confirmatory evidence it agreed to.

Why this case study matters

Unlike some other withdrawn drugs on this site, there's no safety signal or failed confirmatory trial behind Luveris's exit — the confirmatory trial simply never happened, and the FDA's accelerated-approval framework requires withdrawal when that's the case rather than letting an unconfirmed approval sit indefinitely. Worth knowing if you're researching how the accelerated-approval pathway is actually supposed to work in practice, not just in theory.